Cytek Biosciences, Inc. CTKB
5.93 USD -0.03 (-0.50%)
Nov 4, 2026, 11:26 AM EST
5.85 Day range 6.09
3.31 52-week range 6.34
- YTD
- +17.43%
- 1 year
- +51.66%
Analyst view
Consensus: buy
Buy
Price target (mean) 8.40 +41.7% upside
Now 5.93
- Target (low)
- 7.00
- Target (mean)
- 8.40
- Target (high)
- 9.00
Ratings (0m) 6 4 buy · 2 hold · 0 sell
- Strong buy2
- Buy2
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.11333 | 0.10 – 0.13 | 0.079 | +43.5% | 61.49M | +4.9% | 3 |
| Next quarter | 0.035 | 0.02 – 0.05 | -0.0116 | +401.7% | 49.24M | +9.8% | 2 |
| Current year | 0.105 | -0.05 – 0.18 | 0.0609 | +72.4% | 204.71M | +5.9% | 4 |
| Next year | 0.21 | 0.13 – 0.37 | 0.105 | +100.0% | 229.77M | +12.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 13, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| May 13, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 6, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Feb 29, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 14, 2023 | Stephens & Co. | Initiated | — | Overweight |
| Nov 9, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 24, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 16, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Jul 19, 2023 | Raymond James | Initiated | — | Market Perform |
| May 11, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| May 10, 2023 | Goldman Sachs | Maintained | — | Buy |
| Mar 7, 2023 | Piper Sandler | Maintained | — | Overweight |
| Mar 2, 2023 | Morgan Stanley | Maintained | — | Equal-Weight |
| Mar 2, 2023 | Goldman Sachs | Maintained | — | Buy |
| Aug 18, 2022 | Piper Sandler | Maintained | — | Overweight |
| Aug 12, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Aug 11, 2022 | Goldman Sachs | Maintained | — | Buy |
| Jul 14, 2022 | Goldman Sachs | Maintained | — | Buy |
| May 16, 2022 | Piper Sandler | Maintained | — | Overweight |
| May 13, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| May 12, 2022 | Goldman Sachs | Maintained | — | Buy |
| Apr 13, 2022 | Goldman Sachs | Maintained | — | Buy |
| Feb 15, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Aug 17, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Aug 17, 2021 | Morgan Stanley | Initiated | — | Equal-Weight |
| Aug 17, 2021 | Goldman Sachs | Initiated | — | Buy |
| Aug 17, 2021 | Piper Sandler | Initiated | — | Overweight |